Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the FoF Overseas median (35 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 04 Jan 2013 – 20 Aug 2026. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one. S&P 500 history starts 25 Jul 2016, so that benchmark is not plotted over this window — pick a shorter range to see it.
View as table
| Date | DSP US Specific Equity Omni FoF |
|---|---|
| 04 Jan 2013 | ₹100.00 |
| 23 Feb 2014 | ₹143.71 |
| 13 Apr 2015 | ₹160.92 |
| 01 Jun 2016 | ₹165.64 |
| 21 Jul 2017 | ₹193.62 |
| 08 Sep 2018 | ₹251.08 |
| 28 Oct 2019 | ₹251.30 |
| 16 Dec 2020 | ₹329.40 |
| 03 Feb 2022 | ₹400.26 |
| 25 Mar 2023 | ₹379.39 |
| 13 May 2024 | ₹477.50 |
| 01 Jul 2025 | ₹546.29 |
| 20 Aug 2026 | ₹767.18 |
| Metric | DSP · Direct · IDCW NAV ₹81.60 Very High risk ★★★☆☆ | Category median FoF Overseas · 35 funds |
|---|---|---|
| +35.71% | +28.94% | |
| +21.75% | +23.31% | |
| +14.46% | +11.78% | |
| +16.23% | +11.50% | |
| +16.13% | +9.83% | |
| +20.62% | — | |
| +13.60% | +9.67% | |
| +13.81% | +8.27% | |
| +13.59% | +8.01% | |
| Risk | ||
| 18.71% | 18.31% | |
| 0.81 | 0.83 | |
| 1.13 | 1.15 | |
| -28.06% | -28.06% | |
| S&P 500 | — | |
| -1.63% | +4.28% | |
| 1.31 | 1.26 | |
| 122.3% | 121.3% | |
| 148.1% | 121.5% | |
| 1.50% | 0.62% | |
| ₹1,240Cr | ₹289.28Cr | |
| None | — | |
| None | — | |
| ₹100 | — | |
| ₹100 | — | |
| — | 18% | |
| Kaivalya Nadkarni · 1.3y | — | |
| 04 Jan 2013 | — | |
| — | — | |
| — | — | |
| 4.3% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.